In our randomised , open-label , phase 2 study , we recruited women ( aged 18 years ) who had measurable platinum-sensitive , relapsed , high-grade serous or endometrioid ovarian , fallopian tube , or primary peritoneal cancer , or those with deleterious germline BRCA1/2 mutations from nine participating US academic medical centres .